Skip to Main Content

Over the past two weeks, several large drug makers have either halted or rolled back prices as political pressure mounts on the pharmaceutical industry.

The moves suggest more than a little political posturing because the Trump administration is trying to follow through on implementing its so-called blueprint for lowering drug costs and, presumably, these companies hope to get something in return.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!